CBP BRD (CREB binding protein bromodomain) inhibition serves as an effective therapeutic target for Parkinson′s disease. The inhibition is followed by negative regulation of a number of macrophage inflammatory genes. It also downregulates G-protein signaling 4 mRNA.
[1]ISOX-INACT is an inactive control probe for the highly-selective inhibitor of the bromodomain of CREB binding protein (CBP BRD) PF-CBP1.